Biotechnology companies STORM Therapeutics and AlidaBio have announced a strategic collaboration to accelerate the development of cancer therapies targeting RNA modifications.  STORM will utilise AlidaBio’s EpiPlex and EpiScout next-generation sequencing (NGS) platforms to detect and quantitatively measure transcript-specific N6-methyladenosine (m6A) RNA modifications, resulting from METTL3 inhibition.   Post-transcriptional modification of RNA, including N6-methyladenosine (m6A), adds a crucial layer of regulation to RNA metabolism, […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!